A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

Investigational New Drugs

Volumn 24, Issue 2, 2006, Pages 141-149

  Peterson, Amy C ^a   Harlin, Helena ^a   Karrison, Theodore ^a   Vogelzang, Nicholas J ^b   Knost, James A ^c   Kugler, John W ^c   Lester, Eric ^d   Vokes, Everett ^a,e   Gajewski, Thomas F ^a   Stadler, Walter M ^a,e  

^a UNIVERSITY OF CHICAGO   (United States)

^b NEVADA CANCER INSTITUTE   (United States)

^c Oncology/Hematology Associates   (United States)

^d Oncology Care Associates   (United States)

^e University of Chicago   (United States)

Author keywords

Bryostatin; Interleukin 2; Phase II trial; Renal cell cancer

Indexed keywords

BRYOSTATIN 1; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLOGY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; EVALUATION; FATIGUE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MYOPATHY; NAUSEA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; T LYMPHOCYTE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; CARCINOMA, RENAL CELL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; T-LYMPHOCYTES; TREATMENT FAILURE;

EID: 33646582949     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-5935-4     Document Type: Article

References (33)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26
2. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408-417
3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540
4. Newton AC (1997) Regulation of protein kinase C. Curr Opin Cell Biol 9:161-167
5. Isakov N, Galron D, Mustelin T, Pettit GR, Altman A (1993) Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J Immunol 150:1195-1204
6. Lee HW, Smith L, Pettit GR, Vinitsky A, Smith JB (1996) Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J Biol Chem 271:20973-20976
7. Dale IL, Gescher A (1989) Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43:158-163
8. Hornung RL, Pearson JW, Beckwith M, Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101-107
9. Jones RJ, Sharkis SJ, Miller CB, Rowinsky EK, Burke PJ, May WS (1990) Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 75:1319-1323
10. Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD (1991) Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51:682-687
11. Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR (2003) Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res 9:109-114
12. Esa AH, Boto WO, Adler WH, May WS, Hess AD (1990) Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors. Int J Immunopharmacol 12:481-490
13. Hess AD, Silanskis MK, Esa AH, Pettit GR, May WS (1988) Activation of human T lymphocytes by bryostatin. J Immunol 141:3263-3269
14. Trenn G, Pettit GR, Takayama H, Hu-Li J, Sitkovsky MV (1988) Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J Immunol 140:433-439
15. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD (1992) Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res 52:548-553
16. Tuttle TM, Bethke KP, Inge TH, McCrady CW, Pettit GR, Bear HD (1992) Bryostatin 1-activated T cells can traffic and mediate tumor regression. J Surg Res 52:543-548
17. Kos FJ, Cornell DL, Lipke AB, Graham LJ, Bear HD (2000) Protective role of IL-2 during activation of T cells with bryostatin 1. Int J Immunopharmacol 22:645-652
18. Mohr H, Pettit GR, and Plessing-Menze A (1987) Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology 175:420-430
19. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F et al. (1993) Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85:1812-1818
20. Stadler WM, Vogelzang NJ (1995) Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol 22:67-73
21. Vogelzang NJ, Lipton A, and Figlin RA (1993) Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 11:1809-1816
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
24. Cuzick JA (1985) Wilcoxon-type test for trend. Stat Med 4:87-90
25. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 53:457-481
26. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132
27. Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maase H (2004) Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer 90:1156-1162
28. Rini BI, Paintal A, Vogelzang NJ, Gajewski TF, and Stadler WM (2002) Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother 25:269-277
29. Ryan CW, Vogelzang NJ, and Stadler WM (2002) A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94:2602-2609
30. Bosco MC, Rottschafer S, Taylor LS, Ortaldo JR, Longo DL, and Espinoza-Delgado I (1997) The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression. Blood 89:3402-3411
31. Curiel RE, Garcia CS, Farooq L, Aguero MF, and Espinoza-Delgado I (2001) Bryostatin-1 and IL-2 synergize to induce IFN-gamma expression in human peripheral blood T cells: implications for cancer immunotherapy. J Immunol 167:4828-4837
32. Khan P, McGown AT, Dawson MJ, Jayson G, Prendiville JA, Pettit GR, and Crowther D (1998) High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. J Chromatogr B Biomed Sci Appl 709:113-117
33. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R (2000) A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89:615- 618